WHO Model Prescribing Information: Drugs Used in Anaesthesia
(1989; 60 pages) [French] Ver el documento en el formato PDF
Índice de contenido
Ver el documentoPreface
Ver el documentoIntroduction
Abrir esta carpeta y ver su contenidoPremedication
Abrir esta carpeta y ver su contenidoGeneral anaesthetics and oxygen
Abrir esta carpeta y ver su contenidoLocal anaesthetics
Abrir esta carpeta y ver su contenidoNon-opioid analgesics
Cerrar esta carpetaOpioid analgesics and antagonists
Ver el documentoMorphine
Ver el documentoPethidine
Ver el documentoNaloxone
Abrir esta carpeta y ver su contenidoMuscle relaxants and cholinesterase inhibitors
Abrir esta carpeta y ver su contenidoBlood substitutes
Abrir esta carpeta y ver su contenidoSolutions for correcting water and electrolyte imbalance
Abrir esta carpeta y ver su contenidoAntacid for use in obstetric practice
Ver el documentoAnaesthesia at the District Hospital
Ver el documentoSelected WHO publications of related interest
Ver el documentoBack cover


Group: opioid antagonist
Injection: 0.4 mg (hydrochloride) in 1-ml ampoule

General information

Naloxone is a semisynthetic opioid antagonist that competes with opioid analgesics for specific receptor sites in the central nervous system. Its effect, which persists for about 45 minutes, occurs within 1-2 minutes of intravenous administration.

Clinical information


To counteract respiratory depression induced by opioids administered during anaesthesia or by opioid overdosage.

Dosage and administration

Post-anaesthetic administration

Adults: 100-400 micrograms i.v. titrated to the needs of the patient and repeated, as necessary, at intervals of 2-3 minutes.

Children: 5-10 micrograms/kg i.v. repeated as above.

Neonates: 10 micrograms/kg i.v., i.m. or subcutaneously immediately after birth.

Opioid overdosage

Adults: 200 micrograms i.v. repeated, as necessary, at 2-minute intervals to a maximum of 10 mg.

Dosage should be reduced in patients with cardiovascular conditions predisposing to dysrhythmias.


• Known hypersensitivity to naloxone.

• Physical dependence on narcotics (naloxone will precipitate an acute withdrawal syndrome in dependent patients).


The use of naloxone to counteract respiratory depression complements other resuscitative measures including maintenance of a clear airway, control of ventilation, cardiac massage, maintenance of an effective circulatory volume and vasopressor therapy. The necessary facilities and equipment for such treatment must be immediately available.

Use in pregnancy

Naloxone should be used during pre-term pregnancy only when the need outweighs any possible risk to the fetus.

Adverse effects

Unnecessarily high doses may cause hypertension and tachycardia. Transient nausea, vomiting, sweating, tachycardia, hypertension and tremor have been reported. Seizures are rare.

Patients with pre-existing cardiovascular disease have occasionally developed ventricular dysrhythmias.


Excessive dosage results in convulsions, raised blood pressure and loss of preexisting opioid analgesia.


Naloxone injection should be kept protected from light.

Ir a la sección anterior
Ir a la siguiente sección
El Portal de Información - Medicamentos Esenciales y Productos de Salud de la OMS fue diseñado y es mantenido por la ONG Human Info. Última actualización: le 29 octubre 2018